A Manchester University NHS Foundation Trust (MFT) doctor has won a celebrated international prize, in recognition for his work in respiratory (breathing related) research.
A pioneering method of delivering research – popularised during the height of the COVID-19 pandemic – is being leveraged for the benefit of Greater Manchester residents.
Research finds interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination doubles antibody response.
A world-first genetic test, developed in Manchester, that could save the hearing of hundreds of babies each year has been successfully piloted in the NHS.
The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.